Loading...
Loading...
In a report published Friday, Morgan Stanley analyst Sean Laaman reiterated an Equal-Weight rating on
ResMedRMD, and raised the price target from $46.19 to $49.57.
In the report, Morgan Stanley noted, “Currency headwinds and part quarter release of the S10 downplayed expectations ahead of the result. Despite this, RMD beat on US revenue driven by a rapid ramp in generator sales of ~8% with gross margins in-line. We upgrade our forecasts as S10 upside and accessory flow are yet to fully emanate.”
ResMed closed on Thursday at $49.57.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in